Key Takeaways ABT's Diabetes Care sales hit $1.90B in Q2 2025, up 19.6% organically with strong FreeStyle Libre demandNew FDA approvals for OTC CGM systems Lingo and Libre Rio expand ABT's consumer reach.ABT to launch dual-analyte CGM with ketone monitoring, targeting intensive insulin users.Abbott Laboratories’ (ABT) Diabetes Care business has become one of its most dynamic growth engines, driven primarily by its FreeStyle Libre continuous glucose monitoring (CGM) platform. In a relatively short span, Free ...